2023
Maternal FGF2 levels associated with child anxiety and depression symptoms through child FGF2 levels
Lebowitz E, Marin C, Orbach M, Salmaso N, Vaccarino F, Silverman W. Maternal FGF2 levels associated with child anxiety and depression symptoms through child FGF2 levels. Journal Of Affective Disorders 2023, 326: 193-197. PMID: 36717031, PMCID: PMC10104478, DOI: 10.1016/j.jad.2023.01.090.Peer-Reviewed Original ResearchConceptsFGF2 levelsDepressive symptomsDepression symptomsChild anxietySymptoms of anxietyRatings of anxietyGrowth factor 2Maternal anxietySymptomsDepressed childrenDepressionChild depressionMothersChildrenFactor 2Self-report ratingsAnxietyIntergenerational pathwaysNon-referred childrenRange of anxietyFGF2AssociationLevelsMaternal
2017
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed models
1995
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation
Goodman W, McDougle C, Price L, Barr L, Hills O, Caplik J, Charney D, Heninger G. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation. Biological Psychiatry 1995, 38: 138-149. PMID: 7578657, DOI: 10.1016/0006-3223(94)00235-u.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderDrug-free patientsPlasma prolactin responseSeparate test daysOCD symptomsRatings of anxietySymptom exacerbationIntravenous routeProlactin responseOral administrationSusceptible subgroupsBiochemical measuresObsessive-compulsive symptomsSymptomsRandom orderMCPPTest dayPatientsSignificant increaseDisordersBehavioral findingsFindingsPlaceboExacerbationChlorophenylpiperazine
1989
Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects
Woods S, Krystal J, Heninger G, Charney D. Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sciences 1989, 45: 233-242. PMID: 2503670, DOI: 10.1016/0024-3205(89)90255-5.Peer-Reviewed Original ResearchConceptsHealthy human subjectsClonidine 2 mcg/Pulse rateEffects of alprazolamAnxiety-like effectsHuman subjectsRatings of anxietyOral alprazolamHypotensive effectVentilatory responseMcg/Noradrenergic systemBenzodiazepine receptorsAnxiolytic propertiesNeurobiologic mechanismsClonidineNew drugsAlprazolamAnxiety ratingsSubjective anxietyDrugsAnxietyNormal functioningNeural systemsUseful model system
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply